IPS examines DNDi program to develop pediatric HIV drugs

NewsGuard 100/100 Score
Aug 31 2011

Inter Press Service profiles a program launched by the Drugs for Neglected Diseases Initiative (DNDi) to develop antiretroviral drugs (ARVs) specifically designed for children living with HIV/AIDS. "The program will focus exclusively on developing child-adapted formulations for children under three, the most neglected segment in terms of availability of ARVs. The DNDi hopes to have new pediatric-specific medicines available between 2014 and 2016," IPS writes. The article examines pediatric HIV treatment issues in India, Kenya and Brazil (Frayssinet et al., 8/29).

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Posted in: Child Health News | Disease/Infection News

Tags: , , , , , , , , , ,

Comments (0)

Suggested Reading

Unveiling the key role of RNA modification in HIV-1 survival and replication
New drug candidates show promise to reverse HIV immune evasion
Increased coronary vessel wall thickness linked to heart dysfunction in asymptomatic HIV patients
New research sheds light on how GLP-1 obesity drugs may change food cravings
Sugar abnormalities in the blood may promote biological aging and inflammation in HIV patients
New report on HIV drug resistance: Challenges and recommendations
Researchers receive NIH grant to help develop gene therapy for HIV
Common HIV drugs linked to reduced Alzheimer's disease risk

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Global HIV epidemic cannot be ended without keeping former prisoners, other patients engaged in care